RxDoctor Payments Data

Gregory Cox, MD

Ophthalmology · Hamilton, NJNPI 1386607844

Payments from drug & device makers

$1,280in general payments, 2019–2025

Across 54 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Alcon$178
  • Aerie Pharmaceuticals, Inc.$135
  • Pfizer$126
  • Sun Pharmaceutical Industries Inc.$116
  • Bausch & Lomb Americas Inc.$96
  • plus $339 from 8 others

What the payments were for

  • Food & beverage$1,15590%
  • Education$806%
  • Gifts$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,280 in reported general payments places this provider in the 45th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$318,303
Medicare patients
1,085
Services billed
2,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost125$83,626
RestasisCyclosporine60$80,326
XiidraLifitegrast40$48,885
Cyclosporine43$35,659
VyzultaLatanoprostene Bunod24$23,827
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol59$19,103
CombiganBrimonidine Tartrate/Timolol27$12,051
Alphagan PBrimonidine Tartrate21$11,903
Latanoprost590$9,035
Travoprost37$8,515
Prednisolone Acetate251$8,104
Timolol Maleate124$7,395
Brinzolamide26$5,965
Brimonidine Tartrate54$5,239
Flurbiprofen Sodium180$5,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$290$187,906233 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$96$72,71264 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$26$2,23519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →